Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312697 · ClinicalTrials.gov registry record · Phase 2
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
A Phase 2 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05312697 is a Phase 2 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 2 participants.
The verdict
NCT05312697, a Phase 2 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
Interventions
- BIOLOGICAL Setrusumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312697
The ClinicalTrials.gov registry entry for NCT05312697 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setrusumab is the first listed.
NCT05312697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05312697 about?
NCT05312697 is a clinical study titled "Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta". The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
What is the current status of trial NCT05312697?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-04-28. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT05312697?
The interventions under investigation include: Setrusumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05312697?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.